Sign in
4

Changes in Ownership

Denali Therapeutics Inc. Filed Acc 0001209191-21-002342

President and CEO sold 88,334 shares at an average $74.96 ($6,621,782)

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Watts Ryan J. President and CEO 2021-01-04 Sale −1,300 $65.21 $84,768 2,410,012 I: show line 1 in the form
Watts Ryan J. President and CEO 2021-01-04 Sale −1,700 $66.63 $113,265 2,408,312 I: show line 2 in the form
Watts Ryan J. President and CEO 2021-01-04 Sale −1,224 $68.26 $83,552 2,407,088 I: show line 3 in the form
Watts Ryan J. President and CEO 2021-01-04 Sale −9,900 $70.02 $693,181 2,397,188 I: show line 4 in the form
Watts Ryan J. President and CEO 2021-01-04 Sale −11,896 $70.82 $842,479 2,385,292 I: show line 5 in the form
Watts Ryan J. President and CEO 2021-01-04 Sale −8,683 $71.77 $623,218 2,376,609 I: show line 6 in the form
Watts Ryan J. President and CEO 2021-01-04 Sale −9,443 $72.63 $685,852 2,367,166 I: show line 7 in the form
Watts Ryan J. President and CEO 2021-01-04 Sale −7,322 $73.78 $540,189 2,359,844 I: show line 8 in the form
Open-market sales · 88,334 sh · avg $74.96 · $6,621,782

Table II: Derivative

Insider Date Transaction Shares Price Value Exercise Expires Underlying Owned after D/I
Watts Ryan J. President and CEO 2021-01-04 Grant or award · Restricted Stock Units +60,000 60,000 D: show line 19 in the form
Watts Ryan J. President and CEO 2021-01-04 Grant or award · Stock Option (right to buy) +180,000 180,000 D: show line 20 in the form
Loading xslF345X03/doc4.xml…